Clinical Trial Update: A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP) [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on an ongoing Phase Ib/II clinical trial of STSA-1301, a subcutaneous therapy, for primary immune thrombocytopenia (ITP), inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• STSA-1301

Snippet

Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 1, Phase 2 | Status: RECRUITING